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ABSTRACT
The SCOOP study was a two-arm randomized controlled trial conducted in the UK in 12,483 eligible women aged 70 to 85 years. It
compared a screening program using the FRAX® risk assessment tool in addition to bone mineral density (BMD) measures versus
usual management. The SCOOP study found a reduction in the incidence of hip fractures in the screening arm, but there was no
evidence of a reduction in the incidence of all osteoporosis-related fractures. To make decisions about whether to implement any
screening program, we should also consider whether the program is likely to be a good use of health care resources, ie, is it cost-
effective? The cost per gained quality adjusted life year of screening for fracture risk has not previously been demonstrated in an
economic evaluation alongside a clinical trial. We conducted a “within trial” economic analysis alongside the SCOOP study from the
perspective of a national health payer, the UK National Health Service (NHS). The main outcome measure in the economic analysis
was the cost per quality adjusted life year (QALY) gained over a 5-year time period. We also estimated cost per osteoporosis-related
fracture prevented and the cost per hip fracture prevented. The screening arm had an average incremental QALY gain of 0.0237 (95%
confidence interval –0.0034 to 0.0508) for the 5-year follow-up. The incremental cost per QALY gainedwas £2772 comparedwith the
control arm. Cost-effectiveness acceptability curves indicated a 93%probability of the intervention being cost-effective at values of a
QALY greater than £20,000. The intervention arm prevented fractures at a cost of £4478 and £7694 per fracture for osteoporosis-
related and hip fractures, respectively. The current study demonstrates that a systematic, community-based screening program of
fracture risk in older women in the UK represents a highly cost-effective intervention. © 2018 The Authors. Journal of Bone and
Mineral Research Published by Wiley Periodicals, Inc.
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Introduction
There are approximately 9 million osteoporotic or fragility(low-trauma) fractures worldwide per year.(1) In developed
nations, around 1 in 3 women and 1 in 5 men aged 50 years or
older will suffer a fragility fracture during their remaining
lifetime, most commonly at sites such as the hip, distal forearm,
vertebrae, and humerus. In the UK, around 536,000 people suffer
fragility fractures each year, including 79,000 hip fractures, with
a cost in 2010 estimated at £3.5 billion expected to rise to £5.5
billion per year by 2025.(2) For the individual, a hip fracture can
be devastating with loss of independence, and less than one-
third of patients make a full recovery; mortality at 1 year post-
fracture is approximately 20%.(3) Advances in osteoporosis
management over the last two decades have included the
development of bone-strengthening treatments and also
fracture risk assessment tools, such as FRAX, improving the
ability to target treatment to those most likely to fracture. These
elements provide the potential for a community-based
screening program to reduce fracture rates. The aim of the
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SCOOP (Screening for Prevention of Fractures in Older Women)
trial was to assess the effectiveness and cost-effectiveness of a
FRAX-based screening program for older UK women. The
preceding section is adapted from the SCOOP main trial paper
by Shepstone and colleagues.(4)
The screening program in the SCOOP study used a baseline
questionnaire to assess 10-year risk using the FRAX risk
algorithm.(5) Individuals judged to have sufficiently high risk
were invited to undergo dual-energy X-ray absorptiometry
(DXA)-based bonemineral density (BMD)measurement, and this
information was used to recalculate the 10-year hip fracture
probability. This information was communicated to the partici-
pant and their family doctor. We have recently reported the
effectiveness results,(4) which concluded that there was a
potential to reduce hip fracture rates substantially over 5 years
(hazard ratio [HR]¼ 0.72, p¼ 0.002), though not fractures at
other sites (HR¼ 0.94, p¼ 0.178).
There is extensive literature evaluating the cost-effectiveness
of interventions for osteoporosis. However, this has almost
exclusively used economic modeling. The breadth of this
literature is illustrated by two recent systematic reviews of
models to estimate the cost-effectiveness of preventing
osteoporotic fractures. Si and colleagues examined the
evolution of health economic models aimed at strategies for
preventing osteoporotic fractures and identified 104 studies
relating to 74 different models, published between 1980 and
2013.(6) They found that models have evolved in terms of
complexity and emphasis. Hiligsmann and colleagues looked at
cost-effectiveness analyses of drugs for postmenopausal
osteoporosis and identified 39 studies, published between
2008 and 2013.(7) These authors concluded that active
osteoporotic drugs were generally cost-effective in postmeno-
pausal women over age 60 years, particularly if they had other
risk factors. Many of these studies have estimated outcomes in
terms of cost per quality adjusted life year (QALY). However, we
are aware of no published study that has estimated cost per
QALY using an economic evaluation conducted alongside a
randomized controlled trial of screening to prevent fractures.
The aim of the current study was to use resource-use and
outcome data collected as part of the SCOOP study to estimate
the cost-effectiveness of the SCOOP screening intervention over
a 5-year time horizon.
Materials and Methods
The clinical trial
The SCOOP trial has been described elsewhere.(4,8) In brief,
SCOOP is an evaluation of screening aimed at identifying older
women at increased risk of fragility fractures. The study was
conducted across sevenUK geographical regions as a pragmatic,
randomized controlled trial. A total of 12,483 women, aged 70 to
85 years, were consented into the trial by post via primary care.
Women already on prescriptions for anti-osteoporosis medi-
cines (apart from vitamin D or calcium) were excluded.
Participants randomized to the screening arm had 10-year hip
fracture probabilities computed from clinical risk factors using
the FRAX tool. Those above an age-dependent threshold were
invited to have a BMD assessment using DXA. Individuals
subsequently above a second age-dependent threshold, with
the inclusion of the BMD measure, were recommended for
treatment via their general practitioner (GP). Participants in the
control arm received standard management: This included
referral for DXA scans and anti-osteoporosis treatments if
deemed clinically appropriate by their GP. Data collection
followed at 6 and 12 months post-randomization and then
annually thereafter up to 5 years follow-up. The primary
outcome measure was the proportion of individuals sustaining
at least one osteoporosis-related fracture, the assessment of
which is summarized below. A number of secondary outcomes
measures were also collected in the trial, including hip fractures,
all clinical fractures, mortality, health-related quality of life, and
health care resource use data.
Measurement of outcomes
Data were requested on an annual basis from 2009 to 2014 from
NHS Digital, formerly the Health and Social Care Information
Centre (HSCIC).(9) This comprised admitted patient care (inpa-
tient), outpatient, and accident and emergency (A&E) data sets.
Data were interrogated to identify fractures in study participants
from randomization to the end of follow-up. Primary care
records were also screened for fractures based on their GP Read
codes. Participants could also self-report fractures at each
follow-up. In the case of self-report and A&E reported fractures,
or for other sources where there was missing information on
dates or anatomical site, further verification was sought. This
included requests to primary care practices or searches of
radiological records at local hospitals. Only verified fractures
were included as outcomes.(4)
The main outcome measure used in the economic evaluation
was the quality adjusted life year (QALY). This was assessed using
the 3-level EQ-5D(10) by means of a postal questionnaire and
scored using the published tariff.(11) The EQ-5D was assessed at
baseline, 6 months, 12 months, and then annually thereafter up
to 5 years’ follow-up. We estimated QALY by area under the
curve at these time points assuming a linear relationship
between each EQ-5D value. Any participant who died was
assumed to have an EQ-5D score of 0. A secondary analysis was
performed using cost per fracture avoided for both any probable
osteoporotic-related fracture (defined as fractures of hip, wrist,
and spine) and hip fractures only.
Costs
Cost of the screening intervention
Primary care practices identified eligible women from their lists
who were then invited to participate. Those individuals who
agreed constituted the SCOOP cohort and were randomized to
the intervention or control arms. Those in the intervention arm
had their fracture risk assessed, and participants and GPs were
notified of fracture risk. The resources required to undertake the
relevant processes (BMD measurement via DXA scans, calcula-
tion and clinical review of final fracture risk, written notification
of initial and final fracture risk, and a GP consultation for
identified high fracture risk individuals) were recorded as part of
the SCOOP study. All costs were either costed using data
collected as part of the study or were costed using appropriate
unit cost data.(12,13) A breakdown of these costs is given in
Table 1.
Costs associated with fracture-related health care contacts
Health Resource Group codes (HRGs) were not available from
NHS Digital, therefore, inpatient, outpatient, and A&E data sets
were each run through the HRG 4þ grouper to derive the HRG
2 TURNER ET AL. Journal of Bone and Mineral Research
codes.(14) Costs of resource use were drawn from HRGs linked to
National Health Service (NHS) reference costs via data from
HSCIC.(13) Inpatient stay costs were derived from HRG codes
corresponding to each Finished Consultant Episode (FCE).
Allowances were made for type of admission (elective or
nonelective); length of stay; short stays; and excess bed days. A
short stay was defined as less than 2 days in hospital. A long stay
was costed in the same manner as elective admission costs, but
to reflect non-elective NHS reference cost data. Outpatient
attendances were costed according to speciality and type of
attendance (for example, first or follow-up appointments).
Procedure costs, where recorded, were included. The complete-
ness of A&E data was much lower than inpatient and outpatient
data, leading to the generation of missing HRG codes. A
weighted average cost of £129 per A&E attendance was used in
these cases.(13) Medication data were available for anti-
osteoporosis medicines for the full period of follow-up for all
study participants; these were costed using prices from the
British National Formulary No. 66.(15) All costs are for the year
2013/14 in pounds sterling.
Analysis
A “within trial” economic analysis was undertaken on an
“intention-to-treat” basis from the perspective of a national
health payer, the United Kingdom (UK) NHS. The main cost-
effectiveness analysis used QALYs as the outcome measure
(cost-utility study). Two additional economic evaluations were
performed using osteoporotic fractures and hip fractures as
outcomes (cost-effectiveness studies). The study had a 5-year
horizon, so discounting was used to allow for differential timing
of costs and benefits. Discounting was not used for the first year
of follow-up. In subsequent years, costs, QALYs, and fractures
were discounted using a rate of 3.5%, as recommended by the
National Institute for Health and Care Excellence (NICE).(16)
EQ-5D values were completed by postal questionnaires, with
some telephone questionnaire completion for nonresponders.
Response rates were high in the SCOOP study, but complete
data required up to 7 EQ-5D returns over 5 years, thus increasing
the potential for missing data. Missing data is a common
problem in economic analysis and can lead to both bias and a
lack of precision.(17) To estimate QALYs, we needed EQ-5D values
for all points of follow-up when the participant was alive. Each
EQ-5D questionnaire has five questions, all of which need to be
completed to obtain an EQ-5D score. Where there was a single
missing EQ-5D question but the participant had completed the
other four questions, we imputed the missing question using a
“hot-decking” approach.(18) Using this method, the four
completed responses were compared with individuals with
complete data who had the same pattern of responses to those
four items. The missing value was replaced by the modal
response for that item taken from those with complete data.
Individuals with complete EQ-5D data, including those imputed
using hot-decking, were defined as the complete case analysis
(CCA) set. Where participants had missed more than one EQ-5D
question, or where the questionnaire had not been returned,
that EQ-5D score was deemed missing and a QALY could not be
calculated. For these cases, multiple imputation (using five
imputed data sets) was used. Discounted QALY scores were
imputed using the following variables: baseline EQ-5D, age at
randomization, days alive, time without osteoporotic fracture,
and time without hip fracture. Imputation was conducted
separately for each study group.(17) This analysis was conducted
in SPSS version 23 (IBM Corp., Armonk, NY, USA).
Analysis of the costs and outcomes data were undertaken
using seemingly unrelated regression, which allows for correla-
tion between costs and outcomes and is generally considered
robust for skewed data.(19) This was conducted using the sureg
command in STATA (StataCorp, College Station, TX, USA). Both
costs and effects used baseline EQ-5D, age, and study group as
explanatory variables. Means and standard errors from imputed
data were calculated using Rubin’s rules.(20) For the cost per
QALY analysis using imputed QALY data, cost-effectiveness
acceptability curves (CEACs) were estimated using 1000 samples
for each of the five imputed data sets, ie, 5000 samples in total.
For analyses where data were not imputed, CEACs were
estimated using boot-strapping with 2000 samples. CEACs
show the probability that each of the study groups is the most
cost-effective option at different valuations of the outcome
variable.(21) Analyses were performed in SPSS 23 and STATA 11.
Sensitivity analysis
To evaluate the effect of only using cases where we were able to
estimate QALY without multiple imputation, we estimated cost
per QALY for the CCA set. We felt that this would likely provide a
biased estimator because cases were unlikely to be missing at
random. Becausewe had data on cost per fracture avoided for all
Table 1. The Costs of the Screening Intervention
Category of resource use
No. of
items
Cost per
item
Total
cost
SCOOP
denominator
Cost per
person
Identification of eligible patients 52,033 £10.70 £556,753 12483 £44.60
Resource to administer screening questionnaire 6515 £3.65 £23,780 6515 £3.65
Calculation of initial WHO risk algorithm 6233 £0.49 £3054 6233 £0.49
Notification of initial fracture risk, letters to participants and GPs 6233 £1.30 £8103 6233 £1.30
BMD assessment using DXA scans 3064 £69.00 £211,416 6233 £33.92
Calculation of final fracture risk 3064 £0.21 £643 6233 £0.10
Clinical review of final fracture risk 3064 £0.00 £0 6233 £0.00
Notification of final fracture risk result (questionnaireþDXA in
selected cases)
3064 £1.30 £3983 6233 £0.64
Oversight of screening process 6233 £0.00 £0 6233 £0.00
GP consultations 898 £134.00 £120,332 6233 £19.31
Total £104
GP¼general practitioner; BMD¼bone mineral density; DXA¼dual-energy X-ray absorptiometry.
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study participants, we therefore repeated this analysis but
restricted to only those cases in the CCA set. This allowed
assessment of whether the results for cost per fracture when
restricted to the CCA set were similar to results when all data
were used.
Ethical approval was obtained from the North Western–
Haydock Research Ethics Committee of England in Septem-
ber 2007 (REC 07/H1010/70). The trial was registered on the
International Standard Randomized Controlled Trial Register in
June 2007 (ISRCTN 55814835). The Arthritis Research United
Kingdom (ARUK), formerly the Arthritis Research Campaign
(ARC), and the Medical Research Council (MRC) of the UK jointly
funded this trial.
Role of the funding bodies
The funders of the study played no role in the study design, data
collection, data analysis, data interpretation, or writing of this
report. The corresponding author had full access to all data used
in this study and had final responsibility for the decision to
submit for publication.
Results
There were 12,483 participants in the SCOOP study, 6250 in the
control and 6233 in the intervention group. Comparisons of
baseline characteristics between study groups have been
published elsewhere; the two study groups were found to be
very similar.(4) The number of cases for whom we were able to
estimate QALY was 6881 (55%); this comprised 3404 (54%) from
the control group and 3477 (56%) from the intervention group.
When the hot-decking(18) methodwas used to impute responses
when a single EQ-5D question was missing, this rose to 7975
cases (64%); this comprised the CCA set. A comparison of the
CCA set with cases missing one or more EQ-5D values indicated
that missing cases had statistically significantly lower baseline
EQ-5D, more incident fractures, and higher fracture-related
health care costs (Table 2).
The average costs for the intervention were £104 per person
(Table 1). The main components of this cost were case finding,
DXA scans, and GP consultations for identified cases. The total
average discounted costs of both intervention and fracture-
related health care for the 5-year follow-up are given in Table 3;
estimates are provided for both the full data set and the CCA
analysis. For the whole sample, it can be found that estimated
costs are £968 and £900 for the intervention and control groups,
respectively. The major component of costs was inpatient stay
with other secondary care costs also being important. When
costs are examined for the CCA set only, it can be found that
estimated total costs are lower and the difference between the
intervention and control is higher at £104, reflecting a lower
proportion of fractures in the CCA than the whole sample.
Table 4 provides EQ-5D for all available time points for the CCA,
as well as QALY estimates without adjustment for baseline EQ-
5D. Also provided are baseline EQ-5D and unadjusted QALY for
the imputed analysis. Estimates of the discounted QALY
difference for the intervention group compared with the control
are –0.005 and 0.008 for the CCA and imputed analysis,
respectively, neither statistically significantly different. However,
in both cases, baseline EQ-5D values are lower in the
intervention group, which would tend to bias QALY estimates
in favor of the control group.
The results of the economic evaluations are shown in Table 5.
These results were obtained using seemingly unrelated
regression and adjust for differences in baseline age and EQ-
5D. The estimate of incremental QALYs was 0.0237 per person
(95% confidence interval [CI] –0.003 to 0.051). The confidence
interval crosses 0; thus, the difference in QALY is not statistically
significantly at the 5% level. The estimate of the incremental
cost-effectiveness ratio (ICER) was £2772. Also shown in Table 5
are the two analyses of cost per fracture prevented. The
incremental estimate of fractures prevented was 0.0146 (95% CI
0.0002 to 0.029) and 0.0085 (95% CI 0.0026 to 0.0144) for
osteoporotic-related and hip fractures, respectively. These
results are for the 5 years of follow-up. The intervention group
had an incremental cost per fracture prevented of £4478 per
osteoporotic-related fracture and £7694 per hip fracture. The
uncertainty surrounding these estimates are shown in cost-
effectiveness acceptability curves (CEACs) provided in Fig. 1 for
all three analyses. In terms of cost per QALY, there is a 93%
probability the intervention is cost-effective at the NICE
threshold of £20,000 per QALY. For fractures, the CEACs are
slightly lower; for example, there would be an 87% probability
the intervention would be considered cost-effective if prevent-
ing a hip fracture was valued at £20,000.
Sensitivity analysis
The above analysis was repeated for the CCA set, again shown in
Table 5. The incremental effect in terms of QALYs was 0.0214
(95% CI –0.011 to 0.054). The ICER for this analysis was £4646. For
the CCA, the probability that the intervention would be cost-
effective at the NICE threshold of £20,000 per QALY was
approximately 83%. When analysis of osteoporosis-related and
hip fractures was restricted to only those cases that were also in
the CCA data set, we found a marked difference in results
(Table 5). For osteoporotic fractures, the mean estimate of
incremental effect was 0.0094 (95% CI –0.0073 to 0.026). For hip
fractures, the mean estimate of incremental effect was 0.0049
(95% CI –0.0018 to 0.0108). These were both considerably lower
than the values for the whole sample given above. For both
types of fractures, the estimates of effect were no longer
statistically significant between groups and estimated ICERs
were more than double those estimated from the full data sets.
Table 2. Characteristics of Complete Case Analysis and Those Missing Full QALY Data
CCA Missing any EQ-5D Difference p Value
Age (years) 75.2 76.3 1.08 <0.001
No. of incident osteoporotic fractures 0.140 0.194 0.05 <0.001
No. of incident hip fractures 0.023 0.045 0.02 <0.001
Baseline EQ-5D 0.769 0.690 –0.08 <0.001
Total health care costs £781 £1,206 £426 <0.001
QALY¼quality adjusted life year; CCA¼ complete case analysis.
4 TURNER ET AL. Journal of Bone and Mineral Research
Discussion
Participants in the intervention arm accrued, on average, an
additional 0.0237 QALYs, though this difference was not
statistically significant. The additional cost per QALY was
£2772 compared with the control group in our base case
analysis. Although these gains in QALY appear modest given the
5-year follow-up, it should be borne inmind that these aremean
incremental values for the whole of the intervention cohort
compared with the control. Because this is a screening
intervention, the majority of participants in the intervention
arm received no change in their health care and hence would
not be expected to generate a QALY gain. The CEAC presented
in Fig. 1, which allows for the uncertainty inherent in the data,
indicated that at the NICE threshold value of £20,000 for a QALY,
the intervention had a 93% probability of being cost-effective.
The intervention also generated reductions in fractures with a
cost per fracture prevented of £4478 for all osteoporotic
fractures and £7694 for hip fractures. Together, these results
provide strong evidence that screening in the community to
reduce fractures in older women represents an efficient use of
health care resources.
This economic evaluation was based on the SCOOP study. An
important aim of resource data collection was to minimize
burden on participants and achieve high completion rates of
those resources felt likely to be most important in relation to
fractures, eg, fracture-related inpatient care. Data on fracture-
related outcomes and on the resource implications of fracture-
related care were obtained from routine data sources, eg, from
NHS Data. Considerable effort was invested in ensuring these
were as complete as possible. This alsomeant that completeness
of these data was independent of factors that might normally be
expected to affect response, such as poor health. There were
also pragmatic issues related to the research burden of
collecting resource-use data from a large number of practices.
These considerations meant that some items of resource use
were not recorded. Examples included routine primary care
contacts and admissions to nursing homes. The former may
understate some of the costs of providing anti-osteoporosis
medicines should prescription of these drugs lead to an increase
in primary care consultations. The latter might understate any
potential resource savings associated with preventing fractures.
The SCOOP cohort generally had extremely high rates for the
return of questionnaires: At the first follow-up (6-months),
11,967 of 12,483 participants responded (96%), and at the 60-
month follow-up, of the 11,408 participants still living, 10,661
(93%) responded. However, the nature of QALY estimation using
a repeated series of EQ-5D questionnaires makes estimation of
QALYs vulnerable to problems of missing data. Additionally, if
participants would be less likely to return EQ-5D in the period
immediately after a fracture, there may be fewer observations in
a time period that would be expected to have the largest effect
on EQ-5D scores. Furthermore, because the EQ-5D were
completed at set times, it is possible that acute changes in
quality of life secondary to a fracture that had occurred 6months
prior, for example, might not be captured. Because the
comparison of the CCA with missing data (Table 2) and results
for cost per fracture prevented when restricted to the CCA data
(sensitivity analysis, Table 5) indicated that results were likely to
be biased for the CCA data, we used imputed data as our base
case QALY analysis.
A number of modeling studies have evaluated the cost-
effectiveness of osteoporotic fracture prevention for the
UK(22–25) or for a number of different countries including the
UK.(26–30) UK-based models have generally found treatment for
osteoporosis to be cost-effective but have found variations in
Table 3. Total Costs in Both Arms of the Study by Cost Category
Whole sample CCA
Cost type Control Intervention Difference (95% CI) Control Intervention Difference (95% CI)
Inpatient £531 £482 –49.6 (–133, 34) £393 £378 –14.5 (–105, 76)
A&E £162 £160 –2 (–10.7, 6.7) £138 £134 –3.9 (–13, 6)
Outpatient £191 £201 9.8 (–4, 24) £181 £194 12.6 (–5, 30)
Medicines £8 £13 5.6 (3.5, 7.8) £8 £14 5.7 (3, 8)
Non-SCOOP DXA £9 £9 –0.1 (–0.6, 0.4) £9 £9 0.4 (–0.2, 1)
Cost of intervention – £104 – – £104 –
Total £900 £968 68 (–21, 157) £728 £833 104 (8, 201)
CCA¼ complete case analysis; CI¼ confidence interval; A&E¼ accident and emergency; DXA¼dual-energy X-ray absorptiometry.
Table 4. Unadjusted EQ-5D and QALY Estimates for Both Complete Case Analysis (CCA) and Imputed Analysis
Control Intervention Difference Lower 95% CI Upper 95% CI
CCA EQ-5D—baseline 0.773 0.764 –0.009 –0.018 0.001
CCA EQ-5D—6 months 0.760 0.759 –0.001 –0.011 0.009
CCA EQ-5D—12 months 0.750 0.754 0.004 –0.007 0.014
CCA EQ-5D—24 months 0.736 0.734 –0.002 –0.013 0.009
CCA EQ-5D—36 months 0.712 0.710 –0.002 –0.014 0.010
CCA EQ-5D—48 months 0.690 0.693 0.003 –0.010 0.015
CCA EQ-5D—60 months 0.671 0.666 –0.005 –0.018 0.009
CCA discounted QALY 3.373 3.368 –0.005 –0.051 0.040
Imputed analysis baseline EQ-5D 0.743 0.738 –0.006 –0.014 0.002
Imputed analysis discounted QALY 3.266 3.274 0.008 –0.028 0.044
QALY¼quality adjusted life year; CI¼ confidence interval.
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estimates of cost-effectiveness. Factors likely to be important
were reported as prevalence of osteoporosis, costs of treating
fractures, and costs of treatment. One UK study also evaluated
the cost-effectiveness in relation to risk of fracture.(25) Treatment
in cases with higher risk of fractures was associated with
increased probability of being cost-effective, suggestion strate-
gies to identify higher-risk individuals could be beneficial. The
disadvantages of a modeling approach include the requirement
for data from a variety of sources and the necessity for a number
of assumptions to be made. All primary data used in the current
study came from the same source, ie, the SCOOP study. We are
aware of no other study that has conducted an economic
evaluation looking at cost per QALY alongside a randomized
study for the prevention of osteoporotic fractures.
The SCOOP study also differs from a number of the published
models in its length of follow-up. The effect of variable follow-up
time has been investigated using an economic model.(31) In this
study, Kanis and colleagues investigated the effect on ICERs of a
10-year follow-up compared with lifetime follow-up for 70-year-
old women. Increasing the length of follow-up led to a decrease
in estimated ICERs (ie, improved cost-effectiveness). Further-
more, there is often a selection bias in randomized trials with
those consenting involvement likely to be different in character-
istics from decliners. The clinical study reported that mortality in
SCOOP was less than 50% of that expected based on age
distribution at entry and that generally participants tended to be
better educated and of higher socioeconomic status than those
who declined.(4) Conversely, the SCOOP study also appeared to
have higher than expected numbers of fractures.(4) The fact that
the SCOOP study was randomized controlled trial also may have
affected the costs associated with the screening program. Costs
of identification of £44 were paid to practices to reflect the fact
that this was a task only carried out because of the trial. If this
screening programwas rolled out in practice, these costsmay be
lower. For these reasons, the estimates of cost-effectiveness
from SCOOP may represent conservative ones.
The SCOOP clinical trial demonstrated that community
screening, based upon the FRAX probability of hip fracture,
leads to a significant reduction in hip fractures in older
women.(4) The current study provides strong evidence that
community screening, based upon the FRAX probability of hip
fracture in older women, would likely be cost-effective and
represent an efficient use of health care resources.
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